Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Obsidian Therapeutics Q3 2026 Results: Net Loss of $50.7M, Loss Widens

Obsidian Therapeutics is a clinical-stage biopharmaceutical company focused on developing amsoki-cel (formerly OBX-115). As of November 9, 2026, the company had 61,774,046 shares of common stock outstanding and continues to incur significant financial losses to fund its research and development programs.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-50.7-28.5
Net income-50.7-28.5
EPS (diluted, $ a share)$-1.23$-14.77

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, NASDAQ: OBX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Obsidian Therapeutics, Inc.: key numbers

Share price
$12.36Close, Nov 16
Market cap
$764M
Shares outstanding
61.77MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Obsidian Therapeutics, Inc.

All →
4:09 PM ET 8-K
Financial Results

Obsidian Therapeutics Financial Results

Obsidian Therapeutics reported third quarter 2026 financial results, highlighting a cash position of $324.4 million following its Nasdaq debut and a $350 million financing. The company is advancing its lead TIL cell therapy candidate, amsoki-cel, with enrollment in a registration-enabling melanoma cohort expected to complete in Q1 2027.

Term
3 years

“2026 has been a transformative year so far for Obsidian. In the third quarter, we closed an oversubscribed $350 million financing, completed our transaction with Galera Therapeutics, and debuted on Nasdaq as a publicly traded company.”

Madan Jagasia, M.D., Chief Executive Officer

“The updated data we presented at SITC further strengthen our belief in the program, highlighting amsoki-cel’s consistent, favorable safety profile and encouraging clinical activity in patients with advanced melanoma, including an objective response rate of 67%, median progression-free survival of 8.3 months, and median duration of response not yet reached at median study follow-up of 14.3 months.”

Madan Jagasia, M.D., Chief Executive Officer

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.